{
    "nctId": "NCT00270894",
    "briefTitle": "Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients",
    "officialTitle": "Pilot Trial of Sequential Dose-Dense Neoadjuvant Chemotherapy Plus Herceptin in HER2 Positive Stage II-III Breast Cancer Patients",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasm",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Percentage of Subjects Able to Complete > 85% of the Planned Dose on Schedule",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Non-pregnant females =/\\> 18 years of age\n* Non-inflammatory breast cancer stage IIA - IIIC or high risk node negative\n* Core biopsy of breast demonstrating invasive cancer and documented ER/PgR receptor status\n* Normal cardiac function and adequate hematologic function\n* Human epidermal growth factor receptor 2 protein (HER2) positive\n* No evidence of metastatic disease\n* ECOG Performance Status 0 - 1\n* Women of childbearing potential must agree to using effective contraception while on treatment and for at least 3 months post-treatment\n\nExclusion Criteria:\n\n* Treated with other investigational drugs within 30 days\n* Uncontrolled intercurrent disease or active infection\n* Known sensitivity to e. coli-derived proteins or polysorbate 80\n* Psychiatric illness or social situation that would limit study compliance\n* Pre-existing peripheral neuropathy \\> Grade 1\n* Cancer within 5 years of screening with the exception of surgically cured nonmelanomatous skin cancer; in-situ carcinoma of the cervix; or in-situ carcinoma of the breast\n* Bilateral synchronous breast cancer\n* Inflammatory breast cancer\n* Women who are pregnant or breast feeding",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}